Compare Stocks: ABUS, RCUS, ALMS, and GMTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$4.67 +2.0%	$4.56	$3.31 ▼ $5.38	$904.72M	0.64	1.30 million shs	1.44 million shs
ALMS Alumis	$25.31 +3.7%	$26.19	$3.76 ▼ $31.35	$3.23B	-0.69	902,175 shs	1.22 million shs
GMTX Gemini Therapeutics	$78.84 -1.5%	$74.34	$1.16 ▼ $14.10	$3.42B	-0.12	189,291 shs	262,584 shs
RCUS Arcus Biosciences	$29.50 +2.2%	$27.85	$9.81 ▼ $31.74	$3.67B	0.8	1.12 million shs	1.15 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+1.97%	+0.86%	+2.41%	+10.14%	+38.58%
ALMS Alumis	+3.69%	-8.30%	-12.15%	+10.67%	+472.62%
GMTX Gemini Therapeutics	-0.72%	+3.32%	+6.67%	+19.67%	+35.54%
RCUS Arcus Biosciences	+2.27%	+2.89%	+5.12%	+23.83%	+193.20%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$4.67 +2.0%	$4.56	$3.31 ▼ $5.38	$904.72M	0.64	1.30 million shs	1.44 million shs
ALMS Alumis	$25.31 +3.7%	$26.19	$3.76 ▼ $31.35	$3.23B	-0.69	902,175 shs	1.22 million shs
GMTX Gemini Therapeutics	$78.84 -1.5%	$74.34	$1.16 ▼ $14.10	$3.42B	-0.12	189,291 shs	262,584 shs
RCUS Arcus Biosciences	$29.50 +2.2%	$27.85	$9.81 ▼ $31.74	$3.67B	0.8	1.12 million shs	1.15 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+1.97%	+0.86%	+2.41%	+10.14%	+38.58%
ALMS Alumis	+3.69%	-8.30%	-12.15%	+10.67%	+472.62%
GMTX Gemini Therapeutics	-0.72%	+3.32%	+6.67%	+19.67%	+35.54%
RCUS Arcus Biosciences	+2.27%	+2.89%	+5.12%	+23.83%	+193.20%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	2.50	Moderate Buy	$5.00	7.07% Upside
ALMS Alumis	2.83	Moderate Buy	$40.30	59.23% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
RCUS Arcus Biosciences	2.58	Moderate Buy	$37.80	28.15% Upside

Current Analyst Ratings Breakdown

Latest ABUS, RCUS, ALMS, and GMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$25.00
8/12/2026	ABUS Arbutus Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/10/2026	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$23.00
8/7/2026	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$42.00
8/6/2026	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$41.00 ➝ $43.00
8/6/2026	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$23.00 ➝ $26.00
8/3/2026	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$25.00
7/20/2026	RCUS Arcus Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $45.00
7/17/2026	ABUS Arbutus Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	RCUS Arcus Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	ALMS Alumis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$181.72M	5.08	N/A	N/A	$1.31 per share	3.56
ALMS Alumis	$7.40M	436.17	N/A	N/A	$2.88 per share	8.79
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
RCUS Arcus Biosciences	$117M	32.10	N/A	N/A	$3.64 per share	8.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$33.50M	$0.79	5.91	N/A	N/A	84.22%	90.98%	82.34%	N/A
ALMS Alumis	-$243.32M	-$3.86	N/A	N/A	N/A	-5,933.46%	-95.08%	-75.81%	N/A
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
RCUS Arcus Biosciences	-$353M	-$3.90	N/A	N/A	N/A	-393.16%	-89.54%	-45.61%	10/27/2026 (Estimated)

Latest ABUS, RCUS, ALMS, and GMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ALMS Alumis	-$0.7670	-$1.11	-$0.3430	-$1.11	$3.65 million	$1.66 million
8/12/2026	Q2 2026	ABUS Arbutus Biopharma	-$0.02	-$0.03	-$0.01	-$0.03	$0.70 million	$1.01 million
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	-$0.72	+$0.1712	-$0.72	$21.98 million	$41.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	81.42	54.26
ALMS Alumis	N/A	7.51	7.51
GMTX Gemini Therapeutics	N/A	71.49	71.49
RCUS Arcus Biosciences	0.22	3.82	3.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
ALMS Alumis	N/A
GMTX Gemini Therapeutics	75.42%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	19.90%
ALMS Alumis	33.70%
GMTX Gemini Therapeutics	12.90%
RCUS Arcus Biosciences	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	197.54 million	158.23 million	Optionable
ALMS Alumis	N/A	127.49 million	84.53 million	N/A
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
RCUS Arcus Biosciences	500	127.33 million	117.66 million	Optionable

ABUS, RCUS, ALMS, and GMTX Headlines

Recent News About These Companies

Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?

August 13 at 9:51 PM | insidermonkey.com

Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript

August 13 at 7:37 AM | finance.yahoo.com

Arcus Biosciences Announces New Employment Inducement Grants

August 11, 2026 | businesswire.com

Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says

August 11, 2026 | finance.yahoo.com

Q3 EPS Estimate for Arcus Biosciences Boosted by Analyst

August 10, 2026 | americanbankingnews.com

HC Wainwright Issues Optimistic Forecast for RCUS Earnings

August 10, 2026 | marketbeat.com

Arcus Biosciences Q2 Earnings Call Highlights

August 8, 2026 | marketbeat.com

Wells Fargo & Company Boosts Arcus Biosciences (NYSE:RCUS) Price Target to $26.00

August 8, 2026 | americanbankingnews.com

Arcus Biosciences übertrifft Prognosen für Q2 2026 – Aktie legt zu

August 6, 2026 | de.investing.com

Arcus outlines $5B-$10B casdatifan opportunity as PEAK-1 targets year-end 2026 enrollment and PEAK-20 plans 2026 start

August 6, 2026 | seekingalpha.com

Arcus Biosciences (NYSE:RCUS) Price Target Raised to $26.00

August 6, 2026 | marketbeat.com

Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript

August 5, 2026 | seekingalpha.com

Arcus Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 5, 2026 | seekingalpha.com

Arcus Biosciences (NYSE:RCUS) Releases Earnings Results, Beats Expectations By $0.17 EPS

August 5, 2026 | marketbeat.com

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates

August 5, 2026 | zacks.com

Arcus Biosciences第二季度业绩超预期，股价盘后回升

August 5, 2026 | cn.investing.com

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

August 5, 2026 | businesswire.com

Dimensional Fund Advisors LP Has $30.80 Million Stake in Arcus Biosciences, Inc. $RCUS

August 5, 2026 | marketbeat.com

Earnings To Watch: Arcus Biosciences Inc (RCUS) Q2 2026 -- GF Value Sees 75% Downside

August 4, 2026 | finance.yahoo.com

Arcus Biosciences, Inc. $RCUS Shares Acquired by Renaissance Technologies LLC

August 3, 2026 | marketbeat.com

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

July 29, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ABUS, RCUS, ALMS, and GMTX Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$4.67 +0.09 (+1.97%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$4.67 +0.00 (+0.09%)

As of 08/14/2026 07:58 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Alumis NASDAQ:ALMS

$25.31 +0.90 (+3.69%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$25.05 -0.26 (-1.03%)

As of 08/14/2026 07:58 PM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Gemini Therapeutics NASDAQ:GMTX

$78.84 -1.17 (-1.46%)

As of 08/14/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Arcus Biosciences NYSE:RCUS

$29.50 +0.64 (+2.20%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$29.49 -0.01 (-0.02%)

As of 08/14/2026 07:34 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABUS, RCUS, ALMS, and GMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABUS, RCUS, ALMS, and GMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABUS, RCUS, ALMS, and GMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABUS, RCUS, ALMS, and GMTX Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Alumis NASDAQ:ALMS

Gemini Therapeutics NASDAQ:GMTX

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABUS, RCUS, ALMS, and GMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABUS, RCUS, ALMS, and GMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABUS, RCUS, ALMS, and GMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABUS, RCUS, ALMS, and GMTX Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Alumis NASDAQ:ALMS

Gemini Therapeutics NASDAQ:GMTX

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools